No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Tianjin Lisheng Pharmaceutical Co.,Ltd. specializes in the manufacturing and distribution of chemical pharmaceutical products. Their extensive catalog features a variety of finished dosage forms, including tablets, hard capsules, dripping pills, freeze-dried powder injections, and water injections, alongside bulk medicines. The company also provides pharmaceutical intermediates, diagnostic reagents, biochemical reagents, and plastic bottles. Headquartered in Tianjin, China, the firm extends its reach through product exports. Tianjin Lisheng Pharmaceutical Co.,Ltd. operates as a subsidiary of Tianjin Pharmaceutical Holdings Co., Ltd.
www.lishengpharma.comNo one on the platform currently holds 002393.SZ.
No tracked institution reports a position in 002393.SZ as of their last filing.
No one on the platform has traded 002393.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 13.3% | — | — | — | ||
| Rev. Growth % | 4.2% | 4.1% | ||||
| Profit Margin % | 30.0% | 18.9% | 14.4% | |||
| Free Cash Flow Margin % | 29.8% | |||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.7B | +12.9% | $1.33 | $1.33–$1.33 | — | 1 |
| 2027 | $1.9B | +16.5% | $1.35 | $1.35–$1.35 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 002393.SZTianjin Lisheng Pharmaceutical Co.,Ltd. | $13.36 | -0.67% | $4.0B | — |
| 002262.SZJiangsu Nhwa Pharmaceutical Co., Ltd. | $21.52 | -0.60% | $21.9B | — |
| 002332.SZZhejiang Xianju Pharmaceutical Co.,Ltd. | $8.48 | -1.40% | $8.4B | — |
| 002349.SZJinghua Pharmaceutical Group Co., Ltd. | $8.02 | -2.08% | $6.7B | — |
| 002399.SZShenzhen Hepalink Pharmaceutical Group Co., Ltd. | $9.37 | -0.11% | $11.7B | — |
| 002437.SZHarbin Gloria Pharmaceuticals Co., Ltd |
Source: Financial Modeling Prep · peers by sector/industry
| $3.37 |
| +0.60% |
| $7.5B |
| — |
| DERMJourney Medical Corporation | $7.36 | -0.27% | $203M | — |